These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38016592)

  • 1. In vitro activity of ceftaroline against bacterial isolates causing skin and soft tissue and respiratory tract infections collected in Latin American countries, ATLAS program 2016-2020.
    Mohamed N; Valdez RR; Fandiño C; Baudrit M; Falci DR; Murillo JDC
    J Glob Antimicrob Resist; 2024 Mar; 36():4-12. PubMed ID: 38016592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
    Flamm RK; Sader HS; Jones RN
    Braz J Infect Dis; 2013; 17(5):564-72. PubMed ID: 23916453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
    Karlowsky JA; Biedenbach DJ; Bouchillon SK; Iaconis JP; Reiszner E; Sahm DF
    J Antimicrob Chemother; 2016 Jan; 71(1):162-9. PubMed ID: 26503667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections.
    Piérard D; Stone GG
    J Glob Antimicrob Resist; 2021 Sep; 26():4-10. PubMed ID: 34022417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015-2018.
    Karlowsky JA; Hackel MA; Bouchillon SLK; Lowman W; Kotb REM; Mohamed N; Stone GG; Sahm DF
    J Glob Antimicrob Resist; 2021 Mar; 24():249-256. PubMed ID: 33373731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019-2020.
    Kuraieva A; Cabezas-Camarero G; Kiratisin P; Utt E
    Antibiotics (Basel); 2023 Jul; 12(8):. PubMed ID: 37627657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020.
    Kempf M; Arhin FF; Kuraieva A; Utt E
    Infect Drug Resist; 2024; 17():343-354. PubMed ID: 38312522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018.
    Jean SS; Lee WS; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2021 Aug; 54(4):627-631. PubMed ID: 32451293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.
    Karlowsky JA; Biedenbach DJ; Bouchillon SK; Hackel M; Iaconis JP; Sahm DF
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):194-9. PubMed ID: 27461798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America - results of AWARE surveillance 2012.
    Hoban D; Biedenbach D; Sahm D; Reiszner E; Iaconis J
    Braz J Infect Dis; 2015; 19(6):596-603. PubMed ID: 26481631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
    BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011).
    Flamm RK; Sader HS; Jones RN
    Braz J Infect Dis; 2014; 18(2):187-95. PubMed ID: 24513484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
    Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ; Flamm RK; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018-2019.
    Jean SS; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106016. PubMed ID: 32422316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study.
    Biedenbach DJ; Iaconis JP; Sahm DF
    J Antimicrob Chemother; 2016 Dec; 71(12):3459-3464. PubMed ID: 27559120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.